C4 Therapeutics, Inc.

NASDAQ:CCCC

Biotechnology

Healthcare
$2.48 +2.06%

+$0.08 today

Market cap
$325.01M
Beta
2.93
P/E (TTM)
-4.9
EPS (TTM)
-$0.82
52W Low $1.36High $4.60

Volume 2.75M

Average 2.76M

CCCC Sales of Investments

Cash received from selling or redeeming investments.

C4 Therapeutics, Inc.NASDAQ: CCCC

Sales of Investments · Q1 FY2026 · quarter ended Mar 2026

Sales of investments growth accelerates

Q1 FY2026 sales of investments of $57.03M rose 4.1% year over year, ahead of the -5.3% change in trailing-twelve-month sales of investments. Sequentially, it rose 8.9% from the prior quarter. Over 3 fiscal years it compounded at -8.2% a year.

Context

  • Sales of investments amounted to 609.5% of revenue in FY2025, down 46.0 pp from a year earlier.
  • Sales of investments increased in 1 of the last 3 fiscal years.
  • FY2025 was the lowest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth of +4.1% holds above the trailing-twelve-month pace of -5.3%.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterMar 2026
$57.03M+8.9% QoQ
Last fiscal yearDec 2025
$219.08M-6.1% YoY
LTMMar 2026
$221.34M-5.3% YoY
Sales of Investments past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+4.1%——
1 year-6.1%——
3-year CAGR-8.2%——
5-year CAGR——
10-year CAGR——

Sales of Investments history

USD · from the cash flow

Latest · FY2025
219.08M USD
Year-over-year change
-6.1%
4-year CAGR
-11.0%

Sales of Investments vs competitors

How CCCC compares with its peers on the latest reported figures

  • Peers report in different currencies, so sales of investments is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of -5.3% is the 2nd highest of 6, against a peer median of -28.1%.
  • Sales of investments amounts to 634.9% of revenue for CCCC, versus a peer median of 51.8%.
CCCC Competitors
Sales of Investments for CCCC and competitors
Company Period LTM YoY 3-year CAGR% of revenue
CCCCC4 Therapeutics, Inc.LTM Mar 2026$221.34M USD-5.3%-8.2%634.9%
MOLNMolecular Partners AGLTM Mar 2026CHF 103.25M CHF-59.1%-11.6%—
PEPGPepGen Inc.LTM Mar 2026$82M USD-28.1%——
CDXSCodexis, Inc.LTM Mar 2026$80.87M USD+33.0%—103.6%
MISTMilestone Pharmaceuticals Inc.LTM Mar 2026$59.86M USD-54.2%+48.2%3355.7%
OABIOmniAb, Inc.LTM Mar 2026$59.3M USD-6.4%+799.2%205.1%
ARMPArmata Pharmaceuticals, Inc.LTM Mar 2026$0 USD——0.0%
IMDXInsight Molecular Diagnostics Inc.LTM Mar 2026$0 USD——0.0%
SGMOSangamo Therapeutics, Inc.LTM Mar 2026$0 USD——0.0%
Peer median (excluding CCCC) —-28.1%+48.2%51.8%

Competitors are the stored peer set for CCCC. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(83.89M)(128.18M)(132.49M)(105.32M)(104.99M)
Depreciation & Amortization1.49M1.68M1.88M1.82M1.96M
Deferred Income Tax1.88M0000
Stock-Based Compensation21.51M30.02M27.24M29.66M19.1M
Change in Working Capital(30.09M)(16.78M)(6.94M)7.65M(29.28M)
Accounts Receivables(1.23M)4.24M(10.33M)8.7M701K
Inventory(2.63M)0000
Accounts Payables(1.18M)(3.33M)273K(119K)(468K)
Other Working Capital(25.05M)(17.69M)3.12M(930K)(29.52M)
Other Non-Cash Items2.13M7.32M3.48M1.03M14.52M
Operating Cash Flow(86.97M)(105.94M)(106.84M)(65.16M)(98.69M)
Capital Expenditures(1.28M)(5.5M)(1.71M)(180K)(607K)
Acquisitions (Net)188.06M(63.92M)000
Purchases of Investments(537.74M)(219.53M)(129.9M)(284.32M)(227.07M)
Sales of Investments349.68M283.45M289.96M233.23M219.08M
Other Investing Activities(188.06M)63.92M000
Investing Cash Flow(189.34M)58.42M158.35M(51.27M)(8.6M)
Debt Repayment00(12.5M)00
Common Stock Issued169.47M777K57.67M44.37M126.32M
Common Stock Repurchased00(110K)(194K)(193K)
Dividends Paid00000
Other Financing Activities1.94M370K426K1.16M274K
Financing Cash Flow171.4M1.15M45.49M45.34M126.4M
Effect of Forex Changes00000
Net Change in Cash(104.9M)(46.37M)97M(71.09M)19.1M
Free Cash Flow(88.24M)(111.44M)(108.55M)(65.34M)(99.3M)

C4 Therapeutics, Inc.

NASDAQ:CCCC

Intrinsic Alpha fair value

Locked

Current Price

$2.48

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.